Citigroup Inc Athira Pharma, Inc. Transaction History
Citigroup Inc
- $169 Billion
- Q3 2024
A detailed history of Citigroup Inc transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Citigroup Inc holds 75 shares of ATHA stock, worth $40. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 75
-0.0%
Holding current value
$40
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ATHA
# of Institutions
65Shares Held
16.9MCall Options Held
112KPut Options Held
68K-
Perceptive Advisors LLC New York, NY5.4MShares$2.92 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.61MShares$871,0540.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$806,1070.39% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$806,1070.04% of portfolio
-
Black Rock Inc. New York, NY676KShares$365,1710.0% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $20.4M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...